The article highlights the importance of antifibrinolytic drugs, such as epsilon-aminocaproic acid (EACA) and tranexamic acid (TXA), in reducing blood loss and the need for transfusions in both cardiac and non-cardiac surgeries. These drugs are recognized for their effectiveness without causing significant adverse effects. EACA comes highly recommended for heart surgeries, with no substantial evidence of thrombotic potential, while TXA is noted for its safety and efficacy in reducing transfusion use, with precautions for dose adjustment in renal impairment and seizure risks at doses over 2 g per day.